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Abstract : This study aimed to clarify whether native coronary artery（CA） calcica-
tion before index percutaneous coronary intervention（PCI） has an impact on the 
effectiveness of drug-coated balloon（DCB） angioplasty for the treatment of in-
stent restenosis（ISR）.  100 consecutive patients with 166 ISR lesions underwent 
quantitative coronary angiography（QCA） before and after index PCI and before 
and after DCB angioplasty for ISR.  CA calcication before index PCI was assessed 
by angiography and results were analyzed to reveal the predictive values for target 
lesion revascularization（TLR） and major adverse cardiac events（MACE）.  Dur-
ing 1.03±1.03 years of follow-up, TLR occurred in 44 lesions（26.5％） and MACE 
in 33 patients（33％）.  On multivariate analysis, CA calcication before index PCI
（p=0.016）, and ％ diameter of stenosis（％DS）≥73％（p=0.023） and minimal 
lumen diameter（MLD）<0.65 mm（p=0.001） before DCB angioplasty were 
independent predictors for TLR after DCB angioplasty.  MACE was also associated 
with CA calcication before index PCI（p=0.01）, and ％DS ≥ 73％（p=0.001） and 
MLD<0.65 mm（p=0.01） before DCB angioplasty, but only ％DS≥73％ before 
DCB angioplasty was an independent predictor for MACE after DCB angioplasty
（p=0.039）.  The combination of CA calcication before index PCI and these QCA 
factors before DCB angioplasty was an independent and more powerful predictor for 
MACE than the QCA factors alone（p<0.001）.  Thereafter, the combination of CA 
calcication and ％DS ≥ 73％ before DCB angioplasty stratied the risk of MACE 
after DCB angioplasty（p<0.05）.  CA calcification before index PCI, as well as 
anatomical information at ISR, have an impact on outcome after DCB angioplasty 
for ISR.
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Introduction
　In-stent restenosis（ISR） is still a major issue following percutaneous coronary intervention
（PCI）, and PCI for complex coronary lesions is prone to develop ISR with an incidence of 
more than 20％1，2）.  Coronary artery（CA） calcification often leads to stent underexpansion and 
subsequent adverse events including ISR3，4）.
　Drug-coated balloon（DCB） angioplasty has recently been introduced in interventional 
cardiology and has become an attractive option for the treatment of ISR5）.  Previous studies 
have reported that DCB angioplasty for bare metal stent（BMS）-ISR or drug-eluting stent
（DES）-ISR provides better results compared with plain old balloon angioplasty, such as 
significantly lower recurrent restenosis and target lesion revascularization（TLR）.  Although DCB 
angioplasty was expected to be an alternative to other treatments for ISR, recurrent ISR still 
occurs in clinical practice.
　The SYNTAX score6） and the standard American College of Cardiology/American Heart 
risk score7） include CA calcification data and have been used by interventional cardiologists 
as a guide for the selection of treatment strategies for patients undergoing PCI with stent 
implantation.  When ISR has occurred, angiographic patterns of ISR are associated with the 
incidence of recurrent TLR8）, however, the impact of original CA calcification before the index 
PCI has not been systematically assessed.  This is partly because the stent metal may hamper 
the discrimination of CA calcification behind the implanted stent, since they have a similar 
density on fluoroscopy.  Therefore, we decided to evaluate CA calcification in the original 
angiogram taken at the time of the index PCI, and hypothesized that the presence of CA 
calcification before the index PCI is associated with the prognosis after DCB angioplasty.
Materials and methods
Study patients
　This prospective observational study enrolled consecutive ISR patients who underwent PCI 
using DCBs at Showa University Hospital, Tokyo, Japan, from April 2014 to March 2017. 
Inclusion criteria were stable or unstable angina with documented ischemia and significant ISR 
with a percent diameter of stenosis（％DS）≥ 50％.  The study was approved by the School of 
Medicine, Showa University Ethics Committee（Permit Number : 2868）, and written informed 
consent was obtained from all patients.  A total of 150 patients with 199 lesions were treated 
with DCB（SeQuent Please; B. Braun, Melsungen, Germany） angioplasty for BMS-ISR or DES-
ISR during the study period, and finally, 100 patients（age, 70±10 years ; 83％ male） with 166 
lesions who underwent successful DCB angioplasty were followed up.
PCI using DCBs for ISR
　Cardiac catheterization was performed according to standard practice.  At the beginning of the 
procedure, 7,000 to 8,000 units of heparin was administered.  The PCI strategy was dependent 
on the individual operator ; however, general principles included predilation（balloon-to-vessel 
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ratio of 0.8 to 1.0 and/or balloon-to-previous stent ratio of 1：1） performed with noncompliant 
balloons inflated to high pressures（>18 atm）.  Three different catheters were used to perform 
predilation : Scoreflex balloon catheter（OrbusNeich, Tokyo, Japan）, LacrosseⓇ NSE balloon 
catheter（Goodman, Nagoya, Japan）, or Cutting balloon catheter（Boston Scientific, Marlborough, 
MA, USA）.  Balloon catheters were available in lengths ranging from 10 to 30 mm and 
diameters ranging from 2.0 to 4.0 mm.  DCBs with paclitaxel were inflated at a nominal pressure 
for a minimum of 30 to 60 sec to allow drug delivery to the vessel wall.  All patients were 
prescribed dual antiplatelet therapy with aspirin（100 mg daily） and either clopidogrel（75 mg 
daily） or prasugrel（3.75 mg daily） for at least 3 months.
Angiographic assessment of CA calcification
　Coronary angiography performed at the index PCI was retrospectively reviewed to assess the 
original characteristics of the lesion which induced ISR following stent placement.  Angiographic 
CA calcification of the target lesion before stent implantation was graded according to the 
definition of standard criteria for preprocedural lesion morphology9）; CA calcification was shown 
as readily apparent densities noted within the apparent vascular wall at the site of the stenosis 
and was defined as radiopacities noted without cardiac motion prior to contrast injection（Fig. 1）. 
Fig. 1.   Coronary angiogram showing coronary artery（CA） calcification before the index 
percutaneous coronary intervention（PCI）
CA calcification appears as readily apparent densities noted within the apparent vascular wall at 
the site of the stenosis and was defined as radiopacities noted without cardiac motion prior to 
contrast injection. In a 70-year-old male patient with angina pectoris, coronary angiography showed 
a diffuse CA calcification（A） of the right CA including severe coronary stenosis of segment 1 on 
the American Heart Association classification（B）, and the index PCI with stent improved the CA 
stenosis of the target lesion（C）. He had symptoms with angina pectoris again. CA calcification 
after the index PCI on the coronary angiogram is masked by the stent in the target lesion of 
segment 1（D）.  Coronary angiography showed the severe CA stenosis into the stent（E）, and 
drug-coated balloon angioplasty（F） improved the in-stent restenosis of the target lesion（G）.
Kosuke NOMURA, et al60
Quantitative coronary angiography（QCA）
　Coronary angiography was performed after intracoronary nitrate injection and all images 
before and after interventions were digitally stored.  Quantitative analysis of the coronary 
angiographic images was performed by evaluating the matched orthogonal views in the 
catheterization laboratory using the CAAS V system（Pie Medical Imaging BV, Maastricht, The 
Netherlands）.  Reference vessel diameter, minimal lumen diameter（MLD）, ％DS, and lesion 
length were analyzed by experienced cardiologists, blinded to the clinical procedure and outcomes
（Fig. 2）.  The SYNTAX score for each patient was calculated prospectively by scoring all 
coronary lesions with a ％DS ≥ 50％ in vessels ≥ 1.5 mm using the SYNTAX score algorithm6）. 
An in-stent analysis（from shoulder to shoulder of the dilated DCB） was performed.  Restenosis 
was defined as recurrent ％DS ≥ 50％ and categorized according to the Mehran classification8）: 
type I, focal ISR lesion <10 mm in length; typeⅡ, diffuse intra-stent lesion >10 mm without 
extending outside the margin of the stent; typeⅢ, diffuse proliferative ISR lesion >10 mm and 
extending beyond the margin of the stent; and typeⅣ, ISR lesion with total occlusion.
　Angiographic success was defined as achievement of a final residual stenosis <30％ by visual 
estimate and Thrombolysis In Myocardial Infarction flow grade 3.
Endpoint
　After DCB angioplasty, all patients underwent regular clinical follow-up at the out-patient 
clinic once every 4 to 8 weeks.  The endpoint was major adverse cardiac events（MACE） 
according to the Academic Research Consortium recommendations10）, which included cardiac 
death, non-fatal myocardial infarction（MI）, TLR, and non-TLR.  Binary restenosis after DCB 
Fig. 2.  Quantitative coronary angiography analysis.
MLD, minimal lumen diameter; ％DS, percent diameter 
of stenosis.
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angioplasty was defined as angiography during follow-up showing a ％DS>50％ related to the 
target lesion, with a history of recurrent angina pectoris and objective signs of documented 
ischemia related to the target lesion.  TLR was defined as repeat PCI or CA bypass grafting 
for restenosis of the target lesion following DCB angioplasty to the previously stented segment. 
Non-TLR was defined as PCI or CA bypass grafting for a de-novo lesion during follow-up.
Statistical analysis 
　All continuous variables are shown as mean±tandard deviation.  Comparisons between groups 
were performed with unpaired t tests or Fisher’s exact tests for continuous variables and the chi-
square test for categorical variables.  Associations among the predictors, such as CA calcification 
and QCA data, for TLR and MACE were formally tested by construction of a Cox proportional 
hazards model with regression analysis.  Pearson’s correlation analysis was performed to assess 
dependence.  A receiver-operating characteristic analysis was performed to define cutoff values, 
and the cutoff values were defined by minimizing the expression of（1-sensitivity）2＋（1-
specificity）2.  The patients were divided into 2 groups for the log-rank test with construction of 
Kaplan-Meier curves.  All multivariable analyses employed the forward stepwise method, with 
entry and removal probability values set at 0.1.  Statistical analysis was performed with SPSS for 
Windows, version 20（SPSS Inc., IBM, Chicago, IL, USA）.  A probability value of <0.05 was 
considered significant.
　A total sample size of 100 patients with ISR was required because 30 patients with CA 
calcification and 70 patients without CA calcification were estimated by the traditional technique 
of Cochran’s formula with an allowable error of 5％ at a 95％ confidence level to prove our 
hypothesis, using the fact that ISR occurs in 5％ of patients with CA calcification and 2％ 
of those without CA calcification according to previous studies of ISR after index PCI with 
stentings11，12）.
Results
Patient Characteristics
　During the study period, 100 ISR patients were enrolled in this study.  When the target 
lesions were divided into 2 groups based on the presence or absence of CA calcification before 
the index PCI, CA calcification was noted in 27 patients（27％） with 52 lesions（31.3％）.  
　No significant differences were found between the patients with and without CA calcification 
for age, sex, and cardiovascular risk factors, but the patients with CA calcification had a 
significantly greater history of chronic kidney disease（p<0.001; Table 1）.  Patients with CA 
calcification had higher levels of N-terminal brain natriuretic peptide than those without CA 
calcification（p=0.02）, and were more likely to have left main trunk CA disease or 3 vessel 
disease（p=0.008）.
Lesion characteristics
　The lesions with CA calcification before the index PCI were associated with a higher 
Kosuke NOMURA, et al62
incidence of type I ISR, whereas those without CA calcification were associated with type Ⅳ 
ISR（p=0.006; Table 2）.  
　There were no significant differences in stent type, stent size, balloon types, and DCB size 
between the lesions with and without CA calcification before the index PCI.  When the QCA 
data were analyzed, the lesions with CA calcification before the index PCI had a lower ％DS 
before index PCI and a higher MLD after index PCI than those without CA calcification before 
Table 1.  Patient characteristics
Coronary artery calcication  
before index PCI
Yes（n=27） No（n=73） p value
Age（years）† 72±8 70±11 0.42
Female 7（25.9％） 10（13.7％） 0.23
History of diabetes 18（66.7％） 42（57.5％） 0.49
History of hypertension 24（88.9％） 58（79.5％） 0.38
History of hyperlipidemia 18（66.7％） 55（75.3％） 0.45
History of current smoking 13（48.1％） 46（63.0％） 0.25
History of myocardial infarction 23（74.2％） 42（63.6％） 0.36
History of coronary artery bypass graft 0 5（6.8％） 0.32
History of chronic kidney disease 21（77.8％） 28（38.4％） < 0.001
History of cerebrovascular disease 1（3.7％） 10（13.7％） 0.28
Low-density lipoprotein cholesterol（mg/dl）† 70.0±22.9 80.8±25.7 0.06
High-sensitivity C-reactive protein（mg/dl）† 0.717±1.594 0.420±1.273 0.34
N-terminal brain natriuretic peptide（pg/ml）† 780±1106 260±918 0.02
Echocardiographic LVEF（％）† 47.9±13.2 52.2±9.2 0.07
Coronary angiographic ndings before DCB angioplasty
　SYNTAX score† 14.1±10.0 10.7±10.7 0.15
　Vessels involved: LMT or 3 VD 9（33.3％） 8（11.0％）
 2VD 11（40.7％） 24（32.9％） 0.008
 1VD 7（25.9％） 41（56.2％）
Medications
　Use of ACE or ARB 11（40.7％） 43（58.9％） 0.12
　Use of beta-blocker 13（48.1％） 42（57.5％） 0.50
　Use of calcium antagonist 9（33.3％） 31（42.5％） 0.50
　Use of nitrite drugs 10（37.0％） 20（27.4％） 0.46
　Use of statin 18（66.7％） 66（90.4％） 0.007
　Use of aspirin 27（100％） 70（95.9％） 0.56
　Use of clopidogrel 18（66.7％） 43（58.9％） 0.50
　Use of prasugrel 7（25.9％） 21（28.8％） 0.81
Values are number of patients（％）, unless indicated otherwise. †Mean±standard deviation. PCI： percutaneous 
coronary intervention, LVEF： left ventricular ejection fraction, DCB： drug-coated balloon, LMT： left main trunk 
coronary artery, VD： vessel disease, ACE： angiotensin-converting enzyme inhibitor, ARB： angiotensin-Ⅱ receptor 
blocker.
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Table 2.  Lesion characteristics of coronary angiography
Coronary artery calcication 
before index PCI
Yes（n=52） No（n=114） p value
Coronary angiographic ndings before DCB angioplasty
　Diameter of stenosis on AHA classication ≥ 90％ 35（67.3％） 76（66.7％） >0.99
　DCB vessel: LMT 4（7.7％） 2（1.8％）
LAD 13（25.0％） 58（50.9％） 0.006
LCX 10（19.2％） 20（17.5％）
RCA 25（48.1％） 34（29.8％）
　Ostium lesion 25（48.1％） 19（16.7％） <0.001
　Bifurcation of target lesion 16（30.8％） 38（33.3％） 0.86
　CTO lesion 0 15（13.2％） 0.006
　In-stent classication: TypeⅠ 40（76.9％） 60（52.6％）
TypeⅡ 11（21.2％） 36（31.6％） 0.004
TypeⅣ 1（1.9％） 18（15.8％）
Index PCI ndings
　Stent type: BMS 9（17.3％） 12（10.5％） 0.31
DES 43（82.7％） 102（89.5％）
　Minimum stent diameter<2.5 mm 4（7.7％） 15（13.2％） 0.43
　Maximum stent length ≥ 30 mm 16（30.8％） 49（43.0％） 0.17
DCB angioplasty ndings
　DCB diameter<3 mm 11（21.2％） 40（35.1％） 0.07
　DCB length ≥ 20 mm 48（92.3％） 102（89.5％） 0.59
　Rotational atherectomy 2（3.8％） 5（4.4％） >0.99
　Directional coronary atherectomy 1（1.9％） 2（1.8％） >0.99
　Balloon type before DCB angioplasty
　　Non-complaint balloon 21（40.4％） 29（25.4％） 0.07
　　Semi-compliant balloon 6（11.5％） 5（4.4％） 0.10
　　Scoring balloon 12（23.1％） 39（34.2％） 0.21
　　Cutting balloon 13（25.0％） 41（36.0％） 0.21
QCA ndings†
　Before index PCI
　　Lesion diameter of stenosis（％） 65.4±20.0 73.1±21.9 0.03
　　Minimum lesion diameter（mm） 0.82±0.55 0.64±0.59 0.07
　　Lesion length（mm）（without CTO） 16.6±8.8 18.9±7.4 0.12
　After index PCI
　　Lesion diameter of stenosis（％） 17.3±12.0 18.6±10.8 0.49
　　Minimum lesion diameter（mm） 2.51±0.50 2.28±0.49 0.007
　Before DCB angioplasty
　　Lesion diameter of stenosis（％） 66.8±16.4 71.9±17.9 0.08
　　Minimum lesion diameter（mm） 0.82±0.47 0.69±0.47 0.10
　　Lesion length（mm）（without CTO） 14.9±6.6 18.8±7.3 0.002
　After DCB angioplasty
　　Lesion diameter of stenosis（％） 22.9±12.1 23.2±11.1 0.96
　　Minimum lesion diameter（mm） 2.17±0.59 2.05±0.44 0.15
Values are number of patients（％）, unless indicated otherwise. †Mean±standard deviation. PCI： percutaneous coronary 
intervention, DCB： drug-coated balloon, AHA： American Heart Association, LMT： left main trunk coronary artery, 
LAD： left anterior descending coronary artery, LCX： left circumex coronary artery, RCA： right coronary artery, CTO： 
chronic total occlusion, BMS： bare metal stent, DES： drug-eluting stent, QCA： quantitative coronary angiography.
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the index PCI.  On the other hand, those with CA calcification had a shorter lesion length 
before DCB angioplasty than those without CA calcification（p=0.002）.
Angiographic predictors of targeted ISR
　The ％DS before index PCI was correlated with the ％DS before DCB angioplasty（r=0.174, 
p=0.03）, and MLD before index PCI was correlated with MLD before DCB angioplasty
（r=0.214, p=0.006）.  Lesion length before index PCI was also correlated with lesion length 
before DCB angioplasty（r=0.621, p<0.001）.
Predictors of TLR after DCB angioplasty
　During 1.03±1.03 years of follow-up（up to 2.5 years） after DCB angioplasty, TLRs occurred 
in 44 lesions（26.5％）.  There was no significant difference in the follow-up duration for the 
presence of TLRs between lesions with and without CA calcification（272±117 vs. 342±156 
days, respectively; p=0.10）.  The area under the curve for predicting TLR was greater for ％DS 
before and after DCB angioplasty than for ％DS before and after index PCI（0.62 and 0.65 vs. 
0.51 and 0.52, respectively）, and the area under the curve was also greater for MLD before and 
after DCB angioplasty than for MLD before and after index PCI（0.64 and 0.61 vs. 0.51 and 
0.6, respectively; Fig. 3）.  TLR after DCB angioplasty was 4.8％（1 of 21 lesions） with BMS and 
29.7％（43 of 145 lesions） with DES（p=0.016）.  TLR after DCB angioplasty was associated 
with CA calcification before index PCI（p=0.007） and QCA data, such as ％DS ≥ 73％（p=0.03）, 
MLD<0.65 mm（p=0.002）, and balloon type（p<0.05） before DCB angioplasty, and ％DS ≥ 
26％ after DCB angioplasty（p=0.01; Table 3）.  
　On multivariate analysis, after adjustment for potential confounding variables, CA calcification 
Fig. 3.   Receiver-operating characteristic analysis of quantitative coronary angiography（QCA） data 
for predicting the lesions of target lesion restenosis（TLR） after drug-coated balloon（DCB） 
angioplasty with paclitaxel
QCA data collected included percent diameter of stenosis（％DS）, minimum lesion diameter
（MLD）, and lesion length（LL） before the index percutaneous coronary intervention（Pre iPCI, 
green line） and after the index PCI（Post iPCI, blue line） and before DCB angioplasty（Pre DCB, 
red line） and after DCB angioplasty（Post DCB, black line）.
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before index PCI（hazard ratio ［HR］, 2.23; 95％ confidence interval ［CI］, 1.16-4.29; p=0.016）, 
and ％DS ≥ 73％（HR, 2.03; 95％ CI, 1.1-3.75; p=0.02） and MLD<0.65 mm（HR, 3.37; 95％ 
CI, 1.69-6.67: p=0.001） before DCB angioplasty were independent predictive factors for TLR 
Table 3.  Descriptive variable lesion factors predicting target lesion revascularization
Regression analysis Wald Univariate analysis
Coefcient（beta） χ2 Hazard ratio （95％ CI） p value
Coronary calcication before index PCI 0.835 7.291 2.3（1.26-4.22） 0.007
Coronary angiographic ndings before DCB angioplasty
　Diameter of stenosis on AHA classication ≥ 99％ 0.264 0.691 1.30（0.70-2.43） 0.41
　Left anterior descending artery lesion 0.130 0.180 1.14（0.63-2.07） 0.70
　Chronic total occlusion lesion 0.172 0.151 1.19（0.50-2.83） 0.70
　TypeⅣ ISR classication 0.506 1.816 1.66（0.80-3.47） 0.18
　Diffuse lesion（typeⅡ, Ⅲ, and Ⅳ） ISR classication -0.030 0.009 0.97（0.53-1.77） 0.92
Index PCI ndings
　Drug-eluting stent 1.890 3.486 6.62（0.91-48.11） 0.06
　Stent length ≥ 30 mm 0.362 1.420 1.44（0.79-2.60） 0.23
　Stent diameter<2.5 mm -0.713 3.210 2.04（0.93-4.46） 0.07
DCB angioplasty ndings
　Length ≥ 20 mm 0.596 0.986 1.82（0.56-5.88） 0.32
　Diameter<3 mm -0.346 1.220 1.41（0.76-2.62） 0.27
　Directional coronary atherectomy 0.993 1.960 2.70（0.65-11.30） 0.17
　Non-complaint balloon 0.761 5.910 2.10（1.16-3.95） 0.02
　Semi-compliant balloon 0.181 0.092 1.20（0.37-3.88） 0.76
　Scoring balloon -0.055 0.029 0.95（0.50-1.79） 0.87
　Cutting balloon -0.749 4.310 0.47（0.23-0.96） 0.04
QCA ndings
　Before index PCI
　　Lesion diameter of stenosis ≥ 73％ -0.059 0.038 0.94（0.52-1.71） 0.85
　　Minimum lesion diameter<0.68 mm -0.297 0.889 1.35（0.73-2.49） 0.35
　　Lesion length ≥ 20.7 mm 
　　（without chronic total occlusion） -0.297 0.889 0.74（0.40-1.38） 0.35
　After index PCI
　　Lesion diameter of stenosis ≥ 21％ 0.116 0.146 1.12（0.62-2.04） 0.70
　　Minimum lesion diameter<2.4 mm -0.536 2.920 1.71（0.92-3.16） 0.09
　Before DCB angioplasty
　　Lesion diameter of stenosis ≥ 73％ 0.700 5.020 2.02（1.09-3.72） 0.03
　　Lesion diameter of stenosis ≥ 73％ 
　　and severe calcication before PCI 1.298 14.533 3.66（1.88-7.13） <0.001
　　Minimum lesion diameter<0.65 mm -1.066 9.880 2.91（1.49-5.65） 0.002
　　Minimum lesion diameter<0.65 mm 
　　and severe calcication before PCI 1.706 25.117 5.51（2.83-10.73）<0.001
　　Lesion length ≥ 16.2 mm 
　　（without chronic total occlusion） -0.139 0.162 0.87（0.44-1.71） 0.69
　After DCB angioplasty
　　Lesion diameter of stenosis>26％ 0.780 6.470 2.18（1.2-4.00） 0.01
　　Minimum lesion diameter<1.9 mm -5.930 3.710 1.91（1.00-3.31） 0.054
CI： confidence interval, PCI： percutaneous coronary intervention, DCB： drug-coated balloon, AHA： American 
Heart Association, ISR： in-stent restenosis, QCA： quantitative coronary angiography.
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after DCB angioplasty.
　Further, the combination of CA calcification before index PCI and ％DS ≥ 73％ or MLD<0.65 
mm before DCB angioplasty was an independent and more powerful prognostic factor for TLR 
after DCB angioplasty than QCA data alone（p<0.001）.
Patient factors for predicting MACE
　During the follow-up, MACE were observed in 33 patients（33％）: cardiac death, 2 patients ; 
non-fatal MI, 6 patients ; TLR, 18 patients ; target vessel revascularization, 2 patients ; and non-
TLR, 5 patients.  The presence of MACE after DCB angioplasty was associated with a history 
of chronic kidney disease（p=0.03）, a serum high-sensitivity C-reactive protein（hsCRP） level
≥0.14 mg/dl（p=0.02）, a SYNTAX score≥14（p=0.01）, CA calcification before index PCI
（p=0.01）, and QCA data before DCB angioplasty, such as ％DS≥73％（p=0.001） and MLD<  
0.65 mm（p=0.01; Table 4）.  
　On multivariate analysis, after adjustment for potential confounding variables, ％DS≥73％ 
before DCB angioplasty was an independent predictive factor for MACE after DCB angioplasty
（HR, 2.46; 95％ CI, 1.05-5.79, p=0.039）.  The combination of SYSTAX score ≥14 before DCB 
angioplasty and CA calcification before the index PCI was an independent powerful prognostic 
factor for MACE（p=0.001）.
　Further, the combination of CA calcification before the index PCI and ％DS≥73％ or 
MLD<0.65 mm before DCB angioplasty was an independent and more powerful prognostic 
factor for MACE than QCA data alone（p<0.001）, and the combination of CA calcification 
before index PCI and ％DS≥73％ before DCB angioplasty stratified the risk of MACE after 
DCB angioplasty（p<0.05 ; Fig. 4）.
Discussion
　CA calcification before the index PCI, and ％DS≥73％ and MLD<0.65 mm（p=0.01） before 
DCB angioplasty were associated with TLR and MACE after DCB angioplasty.  Further, the 
combination of these factors was an independent and more powerful prognostic factor for TLR 
and MACE than the QCA data alone, and the combination of CA calcification before the 
index PCI and ％DS≥73％ before DCB angioplasty stratified the risk of MACE after DCB 
angioplasty.
CA calcification for predicting prognosis after DCB angioplasty for ISR
　With the introduction of contemporary new-generation DESs, the rate of repeat 
revascularization due to ISR has decreased, but the ISR rate after PCI is higher if PCI is 
performed in patients with complex coronary lesions, including CA calcification13）.  A greater 
amount of CA calcification impairs stent delivery, and expansion results in a smaller and more 
elliptical stent area14）, which may lead to an increased risk of subsequent cardiovascular events 
after PCI15）.  In patients with peripheral disease, the severity of CA calcification in de novo 
stenotic lesions has been reported to be associated with TLR after DCB angioplasty, and various 
procedures, such as atherectomy and intravascular lithotripsy, from the new generation options 
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Table 4.  Descriptive variable patient factors for predicting major adverse cardiac events
Regression analysis Wald Univariate analysis
Coefcient（beta） χ2 Hazard ratio（95％ CI） p value
Age≥73years 0.314 0.786 1.38（0.68-2.74） 0.38
Left ventricular ejection fraction<52％ -0.159 0.201 1.17（0.58-2.35） 0.65
History of chronic kidney disease 0.793 4.777 2.21（1.09-4.50） 0.03
High-sensitivity C-reactive protein≥0.14 mg/dl 0.861 5.796 2.37（1.17-4.77） 0.02
Coronary artery calcication before index PCI 0.926 6.634 2.52（1.25-5.11） 0.01
Coronary angiographic nding before DCB angioplasty
　SYNTAX score≥14 0.898 6.448 2.45（1.23-4.91） 0.01
　SYNTAX score≥14 before DCB angioplasty 
　　and coronary artery calcication before index PCI 1.532 11.470 4.63（1.91-11.23） 0.001
　Left anterior descending coronary artery lesion 0.301 0.729 1.35（0.68-2.70） 0.39
　Ostium lesion 0.333 0.803 1.40（0.67-2.90） 0.37
　Maximum diameter of stenosis on AHA 
　classication≥99％ 1.152 10.73 3.17（1.59-6.31） 0.001
　LMT or three vessel disease 0.605 2.191 1.83（0.82-4.08） 0.14
　Type Ⅳ in-stent classication 0.679 2.252 1.97（0.81-4.79） 0.13
Index PCI ndings
　Bare metal stent -0.225 0.177 1.25（0.44-3.58） 0.67
　Drug-eluting stent -0.405 0.641 0.67（0.25-1.80） 0.67
　Stent length≥30 mm 0.320 0.835 1.38（0.69-2.74） 0.36
　Stent diameter<2.5 mm -0.234 0.264 1.26（0.52-3.09） 0.61
DCB angioplasty ndings
　Maximum length≥30 mm 0.458 1.711 1.58（0.80-3.14） 0.19
　Minimum diameter<2.5 mm -0.017 0.001 1.02（0.24-4.35） 0.98
　Directional coronary atherectomy lesion 0.590 0.335 1.81（0.24-13.3） 0.56
QCA ndings
　Before index PCI
　　Maximum lesion diameter of stenosis≥78％ 0.065 0.035 1.07（0.54-2.12） 0.85
　　Minimum lesion diameter<0.65 mm -0.017 0.002 1.02（0.49-2.11） 0.96
　　Maximum lesion length≥22 mm（without CTO） 0.765 3.605 2.15（0.98-4.73） 0.06
　After index PCI
　　Maximum lesion diameter of stenosis≥21％ 0.278 0.620 1.32（0.66-2.63） 0.43
　　Minimum lesion diameter<2.2 mm -0.536 2.168 1.71（0.84-3.50） 0.14
　Before DCB angioplasty
　　Maximum lesion diameter of stenosis≥73％ 1.271 10.510 3.56（1.65-7.69） 0.001
　　Maximum lesion diameter of stenosis≥73％ 
　　　and coronary calcication before index PCI 1.385 13.470 4.00（1.91-8.38） <0.001
　　Minimum lesion diameter<0.65 mm -0.989 6.335 2.69（1.24-5.81） 0.01
　　Minimum lesion diameter<0.65 mm 
　　　and coronary calcication before index PCI 1.584 15.180 4.87（2.20-10.80）<0.001
　　Maximum lesion length≥17.1 mm（without CTO） -0.094 0.052 1.10（0.49-2.46） 0.82
　After DCB angioplasty
　　Maximum lesion diameter of stenosis>25％ 0.469 1.665 1.60（0.78-3.26） 0.20
　　Minimum lesion diameter<1.86 mm -0.555 2.431 1.74（0.87-3.5） 0.12
CI：confidence interval， PCI：percutaneous coronary intervention, DCB：drug-coated balloon, AHA：American 
Heart Association, LMT：left main trunk coronary artery, QCA：quantitative coronary angiography, CTO：chronic 
total occlusion.
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have been conducted to overcome the great difficulty associated with the presence of calcium16）. 
However, there are currently inadequate data about the use of DCB angioplasty for lesions 
with CA calcification because the calcification behind the implanted stent cannot be accurately 
detected and measured on an angiogram or computed tomography angiography.  Intravascular 
ultrasound or optimal coherence tomography enables accurate detection of CA calcification 
in stents17，18）, and previous studies demonstrated that the magnitude of CA calcification was 
inversely correlated to stent expansion, even after high-pressure balloon inflations19，20）.  Further, 
recent studies reported that the accurate detection of abnormal vessel reactions associated with 
stent implantation measured by optimal coherence tomography predicts the prognosis of patients 
undergoing DCB angioplasty after ISR21，22）.  However, in clinical practice, it may be difficult 
to routinely obtain an invasive intravascular assessment of coronary plaque in all patients 
undergoing DCB angioplasty for treatment of ISR because of cost or time-effectiveness.  In 
the present study, we found that angiographical information of CA calcification before DCB 
angioplasty is useful for predicting TLR and MACE after DCB angioplasty.
　Severe CA calcification often requires high-pressure dilation, and the pressure applied from 
the balloon to the vessel wall might not be uniform across the length of the lesion because 
of varying amounts of calcification, which increases the risk of dissection and acute vessel 
Fig. 4.   Combination of coronary artery（CA） calcification before the index percutaneous coronary 
intervention（PCI） and quantitative coronary angiography（QCA） data before drug-coated 
balloon（DCB） angioplasty with paclitaxel for predicting major adverse clinical events
（MACE） in patients after DCB angioplasty
QCA data collected before DCB angioplasty included percent diameter of stenosis（％DS, left 
panel） and minimum lesion diameter（MLD, right panel）.（A）％DS≥73％ or MLD<0.65 mm, 
and CA calcification（CAC ［＋］, black line）;（B） ％DS≥73％ or MLD<0.65 mm, and no CA 
calcification（CAC ［-］, red line）;（C） ％DS<73％ or MLD≥0.65 mm（green line）.  Left panel
（％DS and CAC）: group A vs. B, p=0.049; group B vs. C, p=0.027; group A vs. C, p<0.001. Right 
panel（MLD and CAC）: group A vs. B, p=0.059; group B vs. C, p=0.019; group A vs. C, p<0.001.
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closure, MI, restenosis, and MACE23）.  DCB angioplasty can inhibit neointimal formation by 
homogeneous drug transfer to the vessel wall 5）, but the calcified plaque might prevent the 
transfer of an antiproliferative drug to the vessel wall, and incomplete suppression of neointimal 
hyperplasia might occur.
　Combination of CA calcification and QCA data for predicting prognosis after DCB angioplasty
　It is known that the severity of ischemia is associated with the magnitude of ISR based on 
QCA data24）.  Using QCA data, Rathore et al 25） demonstrated that the focal pattern of ISR and 
baseline ％DS were independent predictors of ISR recurrent restenosis after DCB treatment. 
Rhee et al 26） also demonstrated using QCA data that a composite of cardiac death, target vessel-
related MI, or clinically-indicated TLR during a 2-year follow-up after DCB angioplasty were 
associated with DCB size, ％DS, MLD, and lesion length before DCB angioplasty and residual 
％DS after DCB angioplasty26）.  Similarly, our study showed that ％DS and MLD before 
DCB angioplasty from QCA data were predictors of MACE after DCB angioplasty.  More 
importantly, we found that the combination of CA calcification and QCA data before DCB 
angioplasty was an independent and more powerful prognostic factor for TLR and MACE than 
only QCA data（p<0.001）.
　DES-ISR is associated with poorer outcomes than BMS-ISR after treatment with a DCB, 
whereas index PCI is more effective with DES stenting than BMS stenting in calcified lesions27）. 
On the other hand, Miglionico et al 28） showed a similar event rate after DCB angioplasty in 
ISR lesions between BMS and DES in high-risk patients.  In the present study, MACE after 
DCB angioplasty occurred in 4 of 14 patients（28.6％） who had BMS-ISR and in 29 of 86 
patients（33.7％） who had DES-ISR, with no significant difference between the two groups. 
Furthermore, the balloon type before DCB angioplasty treatment has been also reported to be 
associated with TLR29）, and the use of a cutting balloon improved the prognosis in the present 
study.  However, after adjustment for stent and balloon types, CA calcification and QCA data 
before DCB angioplasty, and the combination of these two factors predicted the prognosis after 
DCB angioplasty independently.
Other factors for predicting prognosis after DCB angioplasty
　The SYNTAX score before the index PCI can be used to stratify risk in patients treated with 
index PCI, and Garg et al 30） demonstrated a poor prognosis after the index PCI in patients with 
a SYNTAX score>17.  On the other hand, the residual SYNTAX score after the index PCI 
with stenting is also reported to predict prognosis31）, but the impact of the SYNTAX score in 
the case of ISR has not been clarified in previous studies.  In the present study, we found that 
higher SYNTAX scores ≥14 before DCB angioplasty predicts MACE after DCB angioplasty in 
patients with ISR.  Further, we found the combination of CA calcification（the SYNTAX score 
number of CA calcification is estimated as 2） and SYNTAX scores ≥14 before DCB angioplasty 
is an independent powerful prognostic factor for MACE after DCB angioplasty（p=0.001）.
　CRP is a sensitive and nonspecific inflammatory marker, and increased CRP levels have 
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been reported to be associated with MACE, including ISR after the index PCI32）.  We showed 
that hsCRP is also predictive of MACE after DCB angioplasty in patients with ISR, similar to 
patients undergoing PCI for native coronary lesions.  Our result indicates that the promotion 
of neointimal proliferation through the stent struts in ISR lesions results from higher hsCRP 
levels33）.
Study limitations
　The major limitations of the present study are the small sample size in a single center. 
Given the rarity of the disease, a large cohort study is warranted to verify these findings.  CA 
calcification before the index PCI was detected retrospectively using cineangiography in patients 
undergoing DCB angioplasty following ISR.  However, the increase in CA calcification after ISR 
compared with before the index PCI may have influenced the prognostic accuracy of predicting 
TLR or MACE after DCB angioplasty.  Further, CA calcification was simply measured using 
cineangiography, sacrificing diagnostic accuracy34）.  Coronary angiography has low-to-moderate 
sensitivity for detecting CA calcification compared with intravascular ultrasound or computed 
tomography, but it is very specific（high positive predictive value）34）.  
Conclusions
　CA calcification before the index PCI and QCA data before DCB angioplasty are associated 
with TLR and MACE after DCB angioplasty, and the combination of these factors is an 
independent and more powerful prognostic factor for TLR and MACE than using QCA data 
alone.  The addition of CA calcification to anatomical information of ISR is important for 
predicting the prognosis of patients, post-DCB angioplasty.  The angiographic anatomical data 
with CA calcification provides important clinical information for selecting the treatment strategy 
for ISR, because the combination of CA calcification and QCA data before DCB angioplasty 
predicts the risk after DCB angioplasty.
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